Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Fulijaya Manufacturing Sdn. Bhd
WARNING LETTER
•Fulijaya Manufacturing Sdn. Bhd•July 18, 2025

Fulijaya Manufacturing Sdn. Bhd – FDA Warning Letter, Jul 18, 2025

Record Details

The FDA issued a Warning Letter to Fulijaya Manufacturing SDN. BHD. following an inspection conducted from July 14-18, 2025. The letter cited significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211), leading to the company"s drug products being deemed adulterated under the Federal Food, Drug, and Cosmetic Act.

Key issues included the failure to ensure complete and original laboratory records, specifically lacking raw data for microbiological release and stability testing, which compromised data integrity. Additionally, the firm failed to establish adequate laboratory controls, exemplified by not performing growth promotion testing for microbiological media or testing a critical component for *Burkholderia cepacia complex*. Finally, the company lacked an adequate stability testing program, with insufficient assay testing for active ingredients and no evaluation for impurities, failing to demonstrate product quality throughout its labeled expiry.

The FDA requires comprehensive investigations into data integrity lapses, risk assessments, and the implementation of a global Corrective and Preventive Action (CAPA) plan. Further required actions include an independent assessment and remediation plan for laboratory practices, retesting of retain samples for distributed products, and a retrospective review of growth media. A comprehensive independent assessment and CAPA for the stability program are also mandated. The FDA strongly recommended engaging a qualified CGMP consultant and requires a written response within 15 working days detailing all corrective actions and a timeline for completion.

Company
Fulijaya Manufacturing Sdn. Bhd
Inspection date
July 18, 2025
Product type
drugs
Office
Center for Drug Evaluation and Research
Person
  • Soo Nam Tan
View Company Profile

ID · 9f6a7af6-80c7-45a3-9d3d-2af25df91ed5

Violation Codes10
FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 CFR 211.166(a)21 CFR 211.160(b)FD&C Act 704(a)(4)21 CFR 21121 CFR 21021 U.S.C. 381(a)(3)21 U.S.C. 374(a)(4)21 CFR 211.34

Full citation text and observation details available on the Dashboard.

Other documents for Fulijaya Manufacturing Sdn. Bhd
  • 483 - 2025-07-18July 18, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fulijaya Manufacturing Sdn. Bhd
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.